Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.